887475-71-0

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
6-Bromo-8-(methylthio)imidazo[1,2-a]pyrazine is utilized as a compound with antimicrobial, antiviral, and anticancer properties, making it a valuable asset in the discovery and development of new pharmaceuticals. Its broad-spectrum biological activities contribute to its potential as a therapeutic agent against various diseases and conditions.
Used in Synthesis of Pharmacologically Active Molecules:
As a building block, 6-Bromo-8-(methylthio)imidazo[1,2-a]pyrazine is employed in the synthesis of a variety of pharmacologically active molecules. Its structural features allow for the creation of new compounds with potential therapeutic uses, expanding the range of available treatments.
Used in Structure-Activity Relationship Studies:
6-Bromo-8-(methylthio)imidazo[1,2-a]pyrazine serves as a useful tool in studying the structure-activity relationships of biologically active compounds. Understanding how the compound's structure influences its biological activity can guide the design of more effective drugs.
Used in Mechanism of Action Research:
6-Bromo-8-(methylthio)imidazo[1,2-a]pyrazine is also applied in research aimed at elucidating the mechanisms of action of biologically active compounds. Insights gained from such studies can enhance the understanding of disease processes and the development of targeted therapies.

Upstream product

• 63744-22-9 6,8-dibromoimidazo[1,2-a]pyrazine 
• 5188-07-8 sodium thiomethoxide 
• 1057261-12-7 6,8-dibromoimidazo[1,2-a]pyrazine hydrobromide 

Downstream Products

• 936360-80-4 6-bromo-3-iodo-8-methylsulfanyl-imidazo[1,2-a]pyrazine 
• 887475-73-2 C₁₇H₁₈N₄O₂S 
• 887475-72-1 C₁₇H₁₈N₄O₂S 
• 1338249-35-6 C₁₇H₁₃ClN₆O₂ 
• 1338249-08-3 C₂₁H₂₁ClN₈O 
• 1094070-46-8 C₈H₉N₃S 
• 1263425-51-9 tert-butyl 3-bromo-8-(methylthio)imidazo[1,2-a]pyrazin-6-yl(cyclohexylmethyl)carbamate 
• 1263425-54-2 3-(4-(cyclopropylcarbamoyl)phenyl)-8-(methylthio)imidazo[1,2-a]pyrazine-6-carboxamide 
• 1263425-55-3 3-(4-(cyclopropylcarbamoyl)phenyl)-8-(methylsulfonyl)imidazo[1,2-a]pyrazine-6-carboxamide 
• 1263423-06-8 N-cyclopropyl-4-(6-(piperidine-1-carbonyl)-8-((tetrahydro-2H-pyran-4-yl)methylamino)imidazo[1,2-a]pyrazin-3-yl)benzamide 
• 1412909-13-7 6-(3-chlorophenyl)-8-(methylthio)-3-p-tolylimidazo[1,2-a]pyrazine 
• 1412909-15-9 8-(methylthio)-6-(3-nitrophenyl)-3-phenylimidazo[1,2-a]pyrazine 
• 1412909-14-8 ethyl 4-(8-(methylthio)-3-phenylimidazo[1,2-a]pyrazin-6-yl)benzoate 
• 1412909-12-6 3-(3,4-dimethylphenyl)-8-(methylthio)-6-(3-(trifluoromethyl)phenyl)imidazo[1,2-a]pyrazine 

Relevant academic research and scientific papers

SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF

A type of substituted penta-fused hexa-heterocyclic compounds having selective inhibition for PIKfyve kinase, a pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with PIKfyve in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.

COMBINATIONS FOR THE TREATMENT OF CANCER

The present invention relates to combinations of at least two compounds A and B, compound A being an inhibitor of Mps-1 kinase, and compound B being an inhibitor of an anti-apoptotic protein of the Bcl-2 family. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of cancer. Another aspect of the present invention relates to the use of an anti- apoptotic protein from the Bcl-2 family as a sensitizer of cells to Mps-1 inhibitors. Another aspect of the present invention relates to the use of the ratio of pro-apoptotic and anti-apoptotic proteins from the Bcl-2 family in a biological sample as a biomarker for a Mps-1 kinase inhibitor treatment.

6-THIO-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS

The present invention relates to substituted imidazopyrazine compounds of general formula (I): (I) in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for prep

SUBSTITUTED 6-IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS

The present invention relates to substituted imidazopyrazine compounds of general formula (I), in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparin

6-THIO-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS

The present invention relates to substituted imidazopyrazine compounds of general formula (I) : (I) in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for pre

SUBSTITUTED 6-IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS

The present invention relates to substituted imidazopyrazine compounds of general formula (I), in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparin

6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS

The present invention relates to substituted imidazopyrazine compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparin

6 SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS

The present invention relates to substituted imidazopyrazine compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparing

Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors

A series of substituted imidazo[1,2-a]pyrazin-8-amines were discovered as novel breast tumor kinase (Brk)/protein tyrosine kinase 6 (PTK6) inhibitors. Tool compounds with low-nanomolar Brk inhibition activity, high selectivity towards other kinases and desirable DMPK properties were achieved to enable the exploration of Brk as an oncology target.

IMIDAZOPYRAZINES

The present invention relates to imidazopyrazine compounds of general Formula (I) : in which X, R1, R2, R3a, R3b, R4a, R4b, R4C, and R4D are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.